NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
Management — NMD Pharma
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
NMD Pharma - PIR International
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "
NMD Pharma - Crunchbase Company Profile & Funding
NMD Pharma - Inkef capital
NMD Pharma - Inkef capital
NMD Pharma Information | NMD Pharma Profile
NMD Pharma - Crunchbase Company Profile & Funding
Company Presentation
Big deal: NMD flexes series A muscles - Global University Venturing
NMD Pharma company information, funding & investors | Dealroom.co
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
PDF) A missense mutation in the putative sarcoplasmic reticulum transmembrane protein DCST2 causes dominant strongman syndrome
Erhverv Aarhus - 照片| Facebook
NMD Pharma A/S | LinkedIn
Prominent Canadian researcher in Denmark: Why I left a top job in California
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9
Company Presentation
NMD Pharma company information, funding & investors | Dealroom.co
Detailed Description | NMD-GPS
NMD Pharma Information | NMD Pharma Profile
